Redeye is encouraged to learn that Orexo has initiated the clinical development of Orexo’s OX640 product, a nasal adrenaline formulation based on Orexo’s novel drug delivery platform amorphOX®.
ANNONS
Redeye is encouraged to learn that Orexo has initiated the clinical development of Orexo’s OX640 product, a nasal adrenaline formulation based on Orexo’s novel drug delivery platform amorphOX®.